tetano
Editor, Senior Moderator
Viruses
. 2024 Jun 12;16(6):947.
doi: 10.3390/v16060947. Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?
César Fernández-de-Las-Peñas[SUP] 1 2 [/SUP], Anabel Franco-Moreno[SUP] 3 [/SUP], María Ruiz-Ruigómez[SUP] 4 [/SUP], Estibaliz Arrieta-Ortubay[SUP] 4 [/SUP], Pablo Ryan-Murua[SUP] 3 5 [/SUP], Carlos Lumbreras-Bermejo[SUP] 4 [/SUP], Pablo Del-Valle-Loarte[SUP] 6 [/SUP], Oscar J Pellicer-Valero[SUP] 7 [/SUP], Rocco Giordano[SUP] 2 8 [/SUP], Lars Arendt-Nielsen[SUP] 2 9 10 [/SUP], Isabel Martín-Garrido[SUP] 11 [/SUP], Juan Torres-Macho[SUP] 3 12 [/SUP]
Affiliations
The aim of this study was to investigate the effects of administrating Remdesivir at the acute COVID-19 phase on developing post-COVID symptoms in previously hospitalized COVID-19 survivors by controlling factors such as age, sex, body mass index, and vaccination status. A case-control study was performed. Hospitalized COVID-19 survivors who had received intravenous Remdesivir during the acute phase (n = 216) were matched by age, sex, body mass index, and vaccination status with survivors who did not receive antiviral treatment (n = 216). Participants were asked to self-report the presence of any post-COVID symptom (defined as a symptom that started no later than three months after infection) and whether the symptom persisted at the time of study (mean: 18.4, SD: 0.8 months). Anxiety levels (HADS-A), depressive symptoms (HADS-D), sleep quality (PSQI), and severity/disability (FIC) were also compared. The multivariate analysis revealed that administration of Remdesivir at the acute COVID-19 phase was a protective factor for long-term COVID development (OR0.401, 95%CI 0.256-0.628) and specifically for the following post-COVID symptoms: fatigue (OR0.399, 95%CI 0.270-0.590), pain (OR0.368, 95% CI 0.248-0.548), dyspnea at rest (OR0.580, 95%CI 0.361-0.933), concentration loss (OR0.368, 95%CI 0.151-0.901), memory loss (OR0.399, 95%CI 0.270-0.590), hair loss (OR0.103, 95%CI 0.052-0.207), and skin rashes (OR0.037, 95%CI 0.005-0.278). This study supports the potential protective role of intravenous administration of Remdesivir during the COVID-19 acute phase for long-lasting post-COVID symptoms in previously hospitalized COVID-19 survivors.
Keywords: antiviral; long-COVID; post-COVID-19; remdesivir.
. 2024 Jun 12;16(6):947.
doi: 10.3390/v16060947. Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?
César Fernández-de-Las-Peñas[SUP] 1 2 [/SUP], Anabel Franco-Moreno[SUP] 3 [/SUP], María Ruiz-Ruigómez[SUP] 4 [/SUP], Estibaliz Arrieta-Ortubay[SUP] 4 [/SUP], Pablo Ryan-Murua[SUP] 3 5 [/SUP], Carlos Lumbreras-Bermejo[SUP] 4 [/SUP], Pablo Del-Valle-Loarte[SUP] 6 [/SUP], Oscar J Pellicer-Valero[SUP] 7 [/SUP], Rocco Giordano[SUP] 2 8 [/SUP], Lars Arendt-Nielsen[SUP] 2 9 10 [/SUP], Isabel Martín-Garrido[SUP] 11 [/SUP], Juan Torres-Macho[SUP] 3 12 [/SUP]
Affiliations
- PMID: 38932239
- DOI: 10.3390/v16060947
The aim of this study was to investigate the effects of administrating Remdesivir at the acute COVID-19 phase on developing post-COVID symptoms in previously hospitalized COVID-19 survivors by controlling factors such as age, sex, body mass index, and vaccination status. A case-control study was performed. Hospitalized COVID-19 survivors who had received intravenous Remdesivir during the acute phase (n = 216) were matched by age, sex, body mass index, and vaccination status with survivors who did not receive antiviral treatment (n = 216). Participants were asked to self-report the presence of any post-COVID symptom (defined as a symptom that started no later than three months after infection) and whether the symptom persisted at the time of study (mean: 18.4, SD: 0.8 months). Anxiety levels (HADS-A), depressive symptoms (HADS-D), sleep quality (PSQI), and severity/disability (FIC) were also compared. The multivariate analysis revealed that administration of Remdesivir at the acute COVID-19 phase was a protective factor for long-term COVID development (OR0.401, 95%CI 0.256-0.628) and specifically for the following post-COVID symptoms: fatigue (OR0.399, 95%CI 0.270-0.590), pain (OR0.368, 95% CI 0.248-0.548), dyspnea at rest (OR0.580, 95%CI 0.361-0.933), concentration loss (OR0.368, 95%CI 0.151-0.901), memory loss (OR0.399, 95%CI 0.270-0.590), hair loss (OR0.103, 95%CI 0.052-0.207), and skin rashes (OR0.037, 95%CI 0.005-0.278). This study supports the potential protective role of intravenous administration of Remdesivir during the COVID-19 acute phase for long-lasting post-COVID symptoms in previously hospitalized COVID-19 survivors.
Keywords: antiviral; long-COVID; post-COVID-19; remdesivir.